International: +1-347-960-6455
Nanotherapies Therapeutics - Pipeline Analysis 2018

Nanotherapies Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10187 Report Type: Molecule-Type Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Nano therapy is a technique derived from nanotechnology, with improved drug solubility and half-life, and enhanced targeted delivery. The size of a nanoparticle ranges from 5 to 500 nm in one dimension. Several nanoparticles are being produced for medical purposes, such as nanotubes, dendrimers, liposomes, micellar systems, and polymer nanoparticles. Some of the nanoparticles such as CYT-6091 and BIND-014 are currently in the clinical stages of development. The poly (lactic-co-glycolic acid) nanoparticles are being formulated for the treatment of solid tumors. Other than medical purpose, the nanoparticles are also being used in imaging techniques, such as ultrasound and magnetic resonance imaging, blood purification techniques, sensing, and tissue engineering.

CytImmune Sciences Inc. is developing CYT-21000 as an immunomodulator for the treatment of solid tumors. Some of the companies developing nanoparticles therapeutic include BBS Nanotechnology Ltd. and Merrimack Pharmaceuticals Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.